Stock comparison
Genmab A/S
Incyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
INCY
Incyte
Market cap
$19.41B
Sector
Healthcare
Overall winner
Incyte INCY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | INCY | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 63C | GMAB |
| Benjamin Graham | 64C | 73B | INCY |
| Philip Fisher | 48D | 61C | INCY |
| Peter Lynch | 25F | 50C | INCY |
| Joel Greenblatt | 76B | 45D | GMAB |
| Charlie Munger | 68C | 60C | GMAB |
| Terry Smith | 71C | 66B | GMAB |
Side-by-side metrics
| Metric | GMAB | INCY |
|---|---|---|
| Market cap | $16.5B | $19.41B |
| P/E (TTM) | 6.2x | 14.0x |
| EV/EBIT | 12.0x | 12.4x |
| ROIC (TTM) | 43.78% | 19.98% |
| Gross margin | 93.88% | 91.86% |
| Net margin | 18.23% | 26.71% |
| Revenue CAGR 5y | -18.45% | 14.55% |
| EPS CAGR 5y | -23.48% | 11.26% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 14.0x+56%
- ROIC (TTM)43.78%vs 19.98%+54%
INCY leads on
- Revenue CAGR 5y14.55%vs -18.45%+179%
- EPS CAGR 5y11.26%vs -23.48%+148%
- Debt / Equity0.0xvs 0.1x+92%
- Net margin26.71%vs 18.23%+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.